NCT03321630View on ClinicalTrials.gov

A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 24, 2017

Primary Completion Date

March 10, 2023

Study Completion Date

January 16, 2024

Conditions
GastroEsophageal CancerGastric Cancer
Interventions
DRUG

Lenvatinib

Lenvatinib 20 mg orally each day on days 1-7

DRUG

Pembrolizumab

Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg

Trial Locations (2)

10016

NYU Langone Health, New York

10029

The Mount Sinai Hospital, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER

NCT03321630 - A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies | Biotech Hunter | Biotech Hunter